Amicus Therapeutics rare disease combo therapy wins FDA nod

The latest stories trending on MedCity News.

Editor's Pick

Top Story Amicus Therapeutics Rare Disease Combo Therapy Wins Long-Awaited FDA Nod Sanofi dominates the market for therapies that treat Pompe disease, a rare enzyme deficiency. The FDA has approved an Amicus Therapeutics combination treatment for patients inadequately served by the Sanofi products. Sponsored Content Remote Patient Monitoring: Gaining Insight into Patient Health from Afar Presented by Greenway Health The era of remote patient monitoring is ushering in a new era of healthcare, characterized by data-driven insights, personalized care, and efficient resource utilization. Learn More>> Please Tell Us What You Think If you haven't already - You still have time to provide us feedback on what works for you and what doesn't on MedCity News. Please take a few moments to share your thoughts. At the end of the survey, you can enter to win a $250 gift card. Thank you. Take Survey Now

Featured News

Payer's Place: Dawn Maroney, Alignment Health CEO of Alignment Health joins the Payer's Place and details how the growth of Medicare Advantage will only help patients in the future. C-SNPs: Promoting Healthcare Focused on Chronic Conditions C-SNPs are Medicare Advantage plans formulated to meet the desired needs of people living with chronic diseases. These plans are different from traditional Medicare plans because they're only available to people who fit the special needs category that the plan serves. 4 States Received Enhanced Medicaid Funding During Covid Despite Wrongly Terminating Coverage New York, Florida, Texas and Minnesota terminated Medicaid coverage for some enrollees for "unallowable or potentially unallowable reasons" during the Covid-19 public health emergency, according to a recent Office of Inspector General report. Ophelia, Vori Health Team Up To Support Patients with Opioid Addiction, MSK Pain Through a new partnership, Vori Health will be able to refer its patients who report having an opioid addiction to Ophelia. On the flip side, Ophelia can refer its patients who report having MSK pain to Vori Health for non-opioid treatment.

Resources

Introducing MedCity FemFwd, a New Podcast on Women's Health In the inaugural episode of the MedCity FemFwd podcast, Michelle Long, senior policy analyst for the Women's Health Policy program at KFF, talks about Opill, which recently made headlines as the first daily oral contraceptive approved for nonprescription use in the U.S. Long tells listeners why this news is significant and examines whether the medication will be covered by insurance. Listen Now

MedCity News • PO Box 901 • New York, NY unsubscribe